The existence of this immune-enhancing LSC founder event is consistent with BCR::ABL1 expression in T-cells in 11 of 20 subjects with CML in TFR [12]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.